Repligen Revenue 2006-2021 | RGEN

Repligen annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Repligen revenue for the quarter ending June 30, 2021 was $0.163B, a 86.32% increase year-over-year.
  • Repligen revenue for the twelve months ending June 30, 2021 was $0.509B, a 68.12% increase year-over-year.
  • Repligen annual revenue for 2020 was $0.366B, a 35.53% increase from 2019.
  • Repligen annual revenue for 2019 was $0.27B, a 39.28% increase from 2018.
  • Repligen annual revenue for 2018 was $0.194B, a 37.38% increase from 2017.
Repligen Annual Revenue
(Millions of US $)
2020 $366
2019 $270
2018 $194
2017 $141
2016 $105
2015 $84
2014 $64
2013 $68
2012 $62
2011 $
2011 $27
2010 $21
2009 $29
2008 $19
2007 $14
2006 $13
2005 $9
Repligen Quarterly Revenue
(Millions of US $)
2021-06-30 $163
2021-03-31 $143
2020-12-31 $109
2020-09-30 $94
2020-06-30 $87
2020-03-31 $76
2019-12-31 $69
2019-09-30 $69
2019-06-30 $71
2019-03-31 $61
2018-12-31 $52
2018-09-30 $50
2018-06-30 $48
2018-03-31 $45
2017-12-31 $42
2017-09-30 $37
2017-06-30 $32
2017-03-31 $31
2016-12-31 $26
2016-09-30 $25
2016-06-30 $29
2016-03-31 $25
2015-12-31 $21
2015-09-30 $20
2015-06-30 $21
2015-03-31 $21
2014-12-31 $16
2014-09-30 $15
2014-06-30 $16
2014-03-31 $16
2013-12-31 $15
2013-09-30 $19
2013-06-30 $18
2013-03-31 $16
2012-12-31 $19
2012-09-30 $15
2012-06-30 $16
2012-03-31 $13
2011-12-31
2011-09-30 $9
2011-06-30 $8
2011-03-31 $6
2010-12-31 $7
2010-09-30 $7
2010-06-30 $7
2010-03-31
2009-12-31 $6
2009-09-30 $5
2009-06-30 $5
2009-03-31
2008-12-31 $6
2008-09-30 $5
2008-06-30 $14
2008-03-31
2007-12-31 $5
2007-09-30 $5
2007-06-30 $6
2007-03-31
2006-12-31 $4
2006-09-30 $3
2006-06-30 $4
2006-03-31
2005-12-31 $3
2005-09-30 $3
2005-06-30 $4
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $17.748B $0.366B
Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS? series of pre-packed `plug-and-play` chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29